Obeticholic acid for people with Barrett's esophagus
Tests obeticholic acid against placebo in adults with Barrett's esophagus.
Key facts
- Who runs it
- National Cancer Institute (NCI)
- Where
- Ann Arbor, Chapel Hill, Cleveland, Kansas City, and St Louis, United StatesSee the 8 sites
- Trial code
- Registry title
- Obeticholic Acid for Prevention in Barrett's Esophagus
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 30 people, planned
- Started
- 3 Jan 2024
- Expected to end
- 1 Sept 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Biospecimen Collection
- Esophageal Biopsy
- Esophagogastroduodenoscopy
- Liver Ultrasonographic Elastography
- Obeticholic Acid
- Placebo Administration
- Questionnaire Administration
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Barrett's esophagus who are already taking proton pump inhibitor (PPI) acid-reducing medicine. It tests obeticholic acid (OCA) against a placebo (dummy pill).
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Barrett's esophagus confirmed by tissue test, with no dysplasia, unclear dysplasia, or low-grade dysplasia (early abnormal cells). At least 2 cm (0.8 in) of the esophagus must be affected. At least one sample must show >= 50% intestinal metaplasia.
- Earlier treatment
- Must be on PPI therapy for >= 28 days. Cannot join after prior ablation of the Barrett's area (radiofrequency ablation, cryotherapy or APC) or prior use of OCA. Must be at least 6 months from any cancer treatment.
Main reasons for not taking part
- High-grade dysplasia or cancer now or in the past on endoscopy
- Chronic liver disease such as cirrhosis, or fatty liver with velocity > 1.7 m/sec on liver elastography
- History of pancreatitis or pancreas problems, or acute gallbladder inflammation
- Active untreated hepatitis B or C; HIV only allowed with CD4+ count >= 300/uL, undetectable viral load and HAART treatment
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 38 criteriaShow less
Who can take part
- Known diagnosis of histologically-confirmed BE with either no dysplasia, indefinite for dysplasia, or low-grade dysplasia as defined by the presence of specialized columnar epithelium on histology and >= 2 cm of involvement on endoscopy
- Adequate Barrett's mucosa, which is defined as at least one sample with >= 50% intestinal metaplasia in biopsies required to satisfy the endpoints of the study
- Participants are on proton pump inhibitors (PPI) therapy for >= 28 days duration
- Age >= of 18 years. Because no dosing or adverse event (AE) data are currently available on the use of OCA in participants < 18 years of age, children are excluded from this study but will be eligible for future pediatric trials, if applicable
- Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)
- Hemoglobin >= 10g/dL or hematocrit >= 30 %
- Leukocyte count >= 3,500/microliter
- Platelet count >= 100,000/microliter
- Creatinine clearance (calculated if measured is not available) >= 30mL/min/1.73m\^2
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 1.5 X institutional upper limit of normal (ULN)
- Total bilirubin =< 1.0 X ULN
- Alkaline phosphatase =<1.5 X ULN
- Gamma-glutamyl transferase (GGT) =< 1.5 X ULN
- The effects of OCA on the developing human fetus are unknown. For this reason, all men and women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, throughout the duration of study participation, and for at least 6 months after receiving the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately
- Ability to understand the study procedures, benefits and risks, and sign a written informed consent document. Non-English speaking participants are allowed to enroll even if they skip answering quality-of-life (QOL) questionnaires. Special efforts will be made through community advisory boards at participating sites to reach Spanish speaking participants
- Willing to undergo testing for human immunodeficiency virus (HIV) testing if not tested within the past 6 months
- Willing to undergo hepatitis B and C screening if not tested within the past 6 months
- Willing and able to adhere to the prohibitions and restrictions specified in the approved protocol
- Willingness to moderate alcohol intake (consuming no more than 1 or 2 alcoholic drinks per day for women and men, respectively)
- Participants must have no evidence of active or recurrent invasive cancer for 6 months prior to screening and must be at least 6 months from any prior cancer-directed treatment (such as surgical resection, chemotherapy, immunotherapy, hormonal therapy or radiation)
Who cannot take part
- History of prior ablative therapy such as radiofrequency ablation, cryotherapy or argon plasma coagulation (APC) in BE segment
- Prior use of OCA
- Prior history or presence of high-grade disease (HGD) or cancer on pre-intervention endoscopy
- Pregnant, breast-feeding, or women of childbearing potential unwilling to use a reliable contraceptive method. Pregnant women are excluded from this study because OCA is an agent with unknown effects on the developing human fetus. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with OCA, breastfeeding should be discontinued if the mother is treated with OCA
- Participants may not be receiving any other investigational agents
- Cutaneous diseases manifesting with severe pruritus
- Individuals with active, known or suspected chronic liver disease including cirrhosis, nonalcoholic steatohepatitis (NASH) with fibrosis or cirrhosis, primary sclerosing cholangitis, biliary atresia
- Individuals with acute cholecystitis (defined by a syndrome of right upper quadrant pain, fever, and leukocytosis associated with gallbladder inflammation)
- Individuals with a history of pancreatitis or pancreatic abnormalities
- History of severe, progressive, or uncontrolled renal, genitourinary, hepatic, hematologic, endocrine, cardiac, vascular, pulmonary, rheumatologic, neurologic, psychiatric, or metabolic disturbances, or signs and symptoms thereof
- Individuals with known hypersensitivity, allergies, or intolerance to the study drug or compounds of similar chemical or biologic composition
- Any serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with participant's safety, obtaining informed consent, or compliance to the study procedures
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Individuals with active and untreated hepatitis C virus (HCV) and/or or hepatitis B virus (HBV) infection
- Individuals with HIV infection are eligible for participation if:; CD4+ count >= 300/uL; Viral load is undetectable; Receiving highly active antiretroviral therapy (HAART) without known or suspected drug interactions with OCA; Consultation with the participant's infectious disease specialist may be obtained
- Individuals taking the drugs listed below may not be randomized unless they are willing to stop the medications (and possibly change to alternative non-excluded medications to treat the same conditions) no less than 5 half-lives days prior to starting OCA or placebo on this study. Consultation with the participant's primary care provider may be obtained but is not required; The use of the following drugs or drug classes is prohibited during OCA/placebo treatment; Investigational agents; Bile acid sequestrants (bile acid binding resins): cholestyramine, colestipol, or colesevelam; Bile salt efflux pump (BSEP) inhibitors; Clozapine; Theophylline derivatives; Tizanidine; Warfarin; Hepatotoxic drugs such as amiodarone, sodium valproate, certain herbal/dietary supplements, and long-term doxycycline or tetracycline
- Individuals with hepatic steatosis and velocity > 1.7 m/sec as determined by liver ultrasound elastography. Results of a right upper quadrant ultrasound with elastography performed within 6 months of starting study treatment may be used to assess this criteria
- Individuals with hyperlipidemia that is not well controlled with the use of pharmacotherapy and/or dietary modifications
Where in United States
- University of Michigan Rogel Cancer CenterAnn Arbor, United StatesContact: Scott M. SchuetzeTaking people
- UNC Lineberger Comprehensive Cancer CenterChapel Hill, United StatesContact: Nicholas J. ShaheenTaking people
- Case Western Reserve UniversityCleveland, United StatesContact: Amitabh ChakTaking people
- Cleveland Clinic FoundationCleveland, United StatesContact: Prashanthi ThotaTaking people
- Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer CenterCleveland, United StatesContact: Joseph E. WillisNot yet recruiting
- University Hospitals Cleveland Medical Center*Cleveland, United StatesContact: Amitabh ChakNot yet recruiting
- University of Kansas Cancer CenterKansas City, United StatesContact: Ajay BansalTaking people
- Washington University School of MedicineSt Louis, United StatesContact: Dayna S. EarlyTaking people
About the trial
What the trial wants to find out
This phase II trial studies the effect of obeticholic acid in treating patients with Barrett's esophagus. Bile acids present in duodenogastroesophageal reflux contribute to neoplastic progression in Barrett's esophagus. Obeticholic acid has shown anti-cholestatic, anti-inflammatory and anti-fibrotic effects mediated by FXR activation. It down regulates bile acid availability and decreases proinflammatory cytokine production including IL-1beta and TNFalpha in human enterocytes and immune cells. This chain of events reduces the bile acid exposure in esophagus tissue thereby limiting bile acid induced damage and dysplastic progression.
The 2 groups in the trial
- Arm I (OCA)Treatment being tested
Patients receive OCA PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients undergo liver ultrasound with elastography during screening, EGD with biopsies, brushings and gastric aspirate at screening and end of treatment visit and blood sample collection throughout the study.
Treatment: Biospecimen Collection, Esophageal Biopsy, Esophagogastroduodenoscopy, Liver Ultrasonographic Elastography, Obeticholic Acid, and Questionnaire Administration
- Arm II (placebo)Placebo, for comparison
Patients receive placebo PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients undergo liver ultrasound with elastography during screening, EGD with biopsies, brushings and gastric aspirate at screening and end of treatment visit and blood sample collection throughout the study.
Treatment: Biospecimen Collection, Esophageal Biopsy, Esophagogastroduodenoscopy, Liver Ultrasonographic Elastography, Placebo Administration, and Questionnaire Administration
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Obeticholic Acid for Prevention in Barrett's Esophagus
- Plain-language title
- Obeticholic acid for people with Barrett's esophagusGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 12 November 2026